Related Experiment Video
Updated: May 5, 2026

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
Published on: May 11, 2015
Should leptin replace insulin as a lifetime monotherapy for diabetes type 1 and 2?
1Department of Neuroscience and McKnight Brain Institute, University of Florida, Florida, USA.
Leptin insufficiency in the hypothalamus causes type 1 and type 2 diabetes. Restoring leptin levels effectively normalized blood glucose in animal models and human clinical trials, offering a new therapeutic strategy.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Neuroscience
Background:
- Adipocyte leptin insufficiency in the hypothalamus is a key factor in diabetes pathogenesis.
- Leptin deficiency disrupts hypothalamic regulation of glucose homeostasis.
- Current diabetes therapies have limitations.
Purpose of the Study:
- To investigate leptin therapy as a treatment for type 1 and type 2 diabetes.
- To evaluate the efficacy of restoring hypothalamic leptin sufficiency.
Main Methods:
- Systemic or central leptin administration in animal models of diabetes.
- Hypothalamic gene therapy to restore leptin levels.
- Clinical trials involving leptin treatment in diabetic patients with lipodystrophy.
Main Results:
- Leptin therapy normalized blood glucose in animal models of type 1 and type 2 diabetes.
- Twice-daily leptin treatment normalized blood glucose in human clinical trials without adverse effects.
- Leptin therapy demonstrated efficacy in both insulin-deficient and hyperinsulinemic diabetic patients.
Conclusions:
- Restoring hypothalamic leptin sufficiency is a viable therapeutic strategy for type 1 and type 2 diabetes.
- Leptin therapy offers a potential alternative to insulin monotherapy.
- Further clinical trials are needed to determine optimal leptin delivery for sustained glycemic control.
More Related Videos
06:16White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
Published on: September 9, 2025
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type I Diabetes II: Pathophysiology
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...